Literature DB >> 12058212

Obstructive jaundice in hepatocellular carcinoma: response after percutaneous transhepatic biliary drainage and prognostic factors.

Joon Woo Lee1, Joon Koo Han, Tae Kyoung Kim, Byung Ihn Choi, Seong Ho Park, Young Hwan Ko, Chang Jin Yoon, Kyung-Mo Yeon.   

Abstract

PURPOSE: To evaluate the therapeutic effect of percutaneous transhepatic biliary drainage (PTBD) in patients with obstructive jaundice caused by biliary involvement of hepatocellular carcinomas (HCC) and to determine the prognostic factors.
METHODS: We retrospectively analyzed the data of 22 consecutive patients (M:F = 20:2, mean age 52.8 years). Inclusion criteria were the patient having obstructive jaundice caused by HCC that invaded the bile ducts and having at least 4 weeks of follow-up data after the PTBD. We defined "good response" and "poor response" as whether the level of total bilirubin decreased more than 50% in 4 weeks or not. Total bilirubin level (T-bil), Child-Pugh score and the location of biliary obstruction for the two groups were compared. In addition, the interval between clinical onset of jaundice and PTBD, the degree of parenchymal atrophy and the size of the primary tumor were compared.
RESULTS: Of the 22 patients, 13 (59.1%) showed good response. T-bil was significantly lower in the good response group than in the poor (14.2 +/- 6 mg/dl vs 25.9 +/- 13.8 mg/dl, p =.017). In the five patients with T-bil <10 mg/dl, four (80%) showed good response, while in nine patients with T-bil > 20 mg/dl, only three (33%) showed good response. Although statistically not significant, patients with Child score <10 showed better results [good response rate of 66.7% (12/18)] than patients with Child score > or = 10 [good response rate of 25% (1/4)]. Involvement of secondary confluence of the bile duct also served as a poor prognostic factor (p = 0.235). The interval between clinical onset of jaundice and PTBD, the presence of parenchymal atrophy and the size of the tumor did not show significant effect.
CONCLUSION: Early and effective biliary drainage might be necessary in this group of patients with limited hepatic function.

Entities:  

Mesh:

Year:  2002        PMID: 12058212     DOI: 10.1007/s00270-001-0100-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  16 in total

Review 1.  Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice.

Authors:  Shuangxi Li; Xuewen He; Lei Dang; Fangyu Xu; Jin Fang; Fenqiang Li; Wenhui Wang
Journal:  Dig Dis Sci       Date:  2018-01-05       Impact factor: 3.199

2.  Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.

Authors:  Eun L Langman; Paul V Suhocki; Herbert I Hurwitz; Michael A Morse; Rebecca A Burbridge; Tony P Smith; Charles Y Kim
Journal:  J Gastrointest Oncol       Date:  2016-12

3.  Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi.

Authors:  Bao-Gang Peng; Li-Jian Liang; Shao-Qiang Li; Fan Zhou; Yun-Peng Hua; Shi-Min Luo
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

4.  Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory?

Authors:  Juil Park; Hyo-Cheol Kim; Jeong-Hoon Lee; EunJu Cho; Minuk Kim; Saebeom Hur; Hwan Jun Jae; Myungsu Lee; Jin Wook Chung
Journal:  Eur Radiol       Date:  2017-11-09       Impact factor: 5.315

5.  Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment.

Authors:  Xiao-Jun Qian; Ren-You Zhai; Ding-Ke Dai; Ping Yu; Li Gao
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

6.  Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma.

Authors:  Gen Sugiyama; Yoshinobu Okabe; Yusuke Ishida; Fumihiko Saitou; Ryuichi Kawahara; Hiroto Ishikawa; Hiroyuki Horiuchi; Hisafumi Kinoshita; Osamu Tsuruta; Michio Sata
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 7.  Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study.

Authors:  Deok-Bog Moon; Shin Hwang; Hee-Jung Wang; Sung-Su Yun; Kyung Sik Kim; Young-Joo Lee; Ki-Hun Kim; Yong-Keun Park; Weiguang Xu; Bong-Wan Kim; Dong Shik Lee; Dong-Hyun Lee; Hong-Jin Kim; Jin Hong Lim; Jin Sub Choi; Yo-Han Park; Sung-Gyu Lee
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

9.  Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma.

Authors:  Dong-Won Ahn; Ju Hyun Shim; Jung-Hwan Yoon; Chung Yong Kim; Hyo-Suk Lee; Yeong Tae Kim; Yoon Jun Kim
Journal:  Korean J Hepatol       Date:  2011-06

10.  Clinical application of percutaneous drainage in treating hepatocellular carcinoma with bile duct tumor thrombus.

Authors:  Zaiming Lu; Wei Sun; Feng Wen; Hongyuan Liang; Ming Shan; Qiyong Guo
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.